{
  "id": 15700466,
  "title": "Arcutis Biotherapeutics director Welgus sells $127,325 in stock",
  "url": "https://urgent.news/2026/10/20/arcutis-biotherapeutics-director-welgus-sells-127-325-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-20T04:31:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/arcutis-biotherapeutics-director-welgus-sells-127325-in-stock-93CH-4958758"
  },
  "original_language": "en",
  "account": null,
  "summary": "Arcutis Biotherapeutics (NASDAQ:ARQT) director Howard G. Welgus sold 4,728 shares of the company's stock on October 15, 2026, for a total of $127,325, as per a pre-arranged 10b5-1 trading plan. The stock has since risen by over 22% in a week, trading at $31.89, nearing its 52-week high of $33.01. Following the sale, Welgus acquired 4,094 shares through exercised stock options, totaling $32,458, bringing his beneficial ownership to 35,207 shares. The company reported a significant increase in second-quarter 2026 revenue, reaching $129.9 million, surpassing forecasts and moving into profitability. Analysts have responded positively, with Guggenheim raising its price target from $35 to $38 and Jefferies maintaining a Buy rating.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}